Cargando...

Profile of infliximab in the treatment of pediatric Crohn’s disease

In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the grow...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatric Health Med Ther
Main Authors: Kierkus, Jaroslaw, Szymanska, Edyta, Oracz, Grzegorz, Wiernicka, Anna, Dadalski, Maciej
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2015
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5683274/
https://ncbi.nlm.nih.gov/pubmed/29388577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S64943
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!